Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mice humanized by syntenic replacement with full-length NLRP3 disease-associated variants model the clinical cryopyrinopathy continuum
John N. Snouwaert, MyTrang Nguyen, Christopher A. Gabel, Ivona Aksentijevich, Jenny P.-Y. Ting, Beverly H. Koller
John N. Snouwaert, MyTrang Nguyen, Christopher A. Gabel, Ivona Aksentijevich, Jenny P.-Y. Ting, Beverly H. Koller
View: Text | PDF
Research Article Genetics Immunology Inflammation

Mice humanized by syntenic replacement with full-length NLRP3 disease-associated variants model the clinical cryopyrinopathy continuum

  • Text
  • PDF
Abstract

Next-generation sequencing technologies are increasingly used to diagnose genetic disorders, particularly immunological diseases with broad and overlapping immune dysregulation. Cryopyrin-associated periodic syndromes (CAPS) are caused by gain-of-function mutations in NLRP3 and include 3 autoinflammatory diseases spanning a continuum of severity: familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease (NOMID). Linking NLRP3 variants to protein dysfunction and clinical phenotype remains challenging because of genetic modifiers and environmental factors. We report the generation and phenotyping of 5 mouse lines expressing either the common human NLRP3 allele or 1 of 4 CAPS mutations spanning the disease spectrum from FCAS to NOMID. In these lines, the murine Nlrp3 locus is replaced by syntenic integration of the human NLRP3 locus, yielding 1 line with the common allele and 4 lines each carrying a distinct CAPS mutation. Unlike models in which a human mutation is introduced into the mouse protein, these lines recapitulate the spectrum of disease severity observed in humans. These findings support a model in which evaluation of nonsynonymous mutations in mice is optimized when introduced in the context of the human gene. This suggests that species-specific regulation and/or intramolecular epistasis may impact modeling of disease-associated variants.

Authors

John N. Snouwaert, MyTrang Nguyen, Christopher A. Gabel, Ivona Aksentijevich, Jenny P.-Y. Ting, Beverly H. Koller

×

Figure 5

Autoinflammatory disease in the CNS of CAPS mouse lines.

Options: View larger image (or click on image) Download as PowerPoint
Autoinflammatory disease in the CNS of CAPS mouse lines.
(A and B) CNS i...
(A and B) CNS inflammation was assessed by quantifying mRNA expression of inflammatory mediators and Gfap, an established marker of astrogliosis. ΔΔCt values for hNLRP3 mice were set to 1; mutants are shown relative to this. (A) Transcript abundance was measured in whole-brain tissue collected from 7-month-old hNLRP3, D305N, and F311S mice. (B) The same panel of inflammation-related transcripts was evaluated in whole-brain mRNA prepared from 8- to 12-week hNLRP3, D305N, and Y572C mice. Analytes include Il1b (IL-1β), Chil3 (chitinase-like 3), Il1rn (IL-1Ra), Tnf (tumor necrosis factor), Gfap (glial fibrillary acidic protein), Mpo (myeloperoxidase), Il6 (interleukin-6), Saa1 (serum amyloid A1), and NLRP3. These markers reflect inflammasome-driven cytokine activity, myeloid activation, and astrocytic reactivity characteristic of CAPS pathology. (C) CNS immune cell infiltration was quantified by flow cytometry. Leukocyte-enriched fractions were prepared from whole-brain homogenates by density gradient separation, and immune cells were enumerated based on CD45 expression. Sample sizes (n) for each genotype are indicated in each panel. Data are presented as mean ± SEM. For A and B, statistical comparisons were performed by 2-tailed unpaired t test between hD305N and hF311S (A) and between hD305N and hY572C (B). For C, asterisks indicate significance for comparisons of each CAPS line to hNLRP3 by 2-tailed unpaired t test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). (C) Red daggers indicate P values for the same comparisons evaluated by 1-way ANOVA with Dunnett’s post-test. (C) A linear-trend analysis was performed using 1-way ANOVA followed by the GraphPad Prism post hoc test for linear trend, revealing a significant monotonic relationship (P = 0.0001). Pairwise comparison between individual CAPS lines is provided in Supplemental Table 6.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts